Discovery of Natural Product-Based Amyloid Inhibitors
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".
Deadline for manuscript submissions: closed (25 January 2024) | Viewed by 8326
Special Issue Editor
Interests: amyloid aggregation; autophagy; natural polyphenols; neurodegenerative diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The positive actions of nutritional supplements and plant extracts in disease prevention are now mainstream and commercial health claims that are being made are subject to strict regulation in most countries. In recent years, increasing interest has been focused on plant polyphenols not only for their antioxidant properties but also due to their ability to inhibit amyloid fibril growth, to favor their disaggregation and to destabilize preformed fibrils. Polyphenols have been shown to abrogate self-assembly of several peptides/proteins associated with amyloid diseases (systemic or neurodegenerative diseases) in different ways depending on the molecular features of either component. The findings reported in the last decade are starting to help to decipher the complex relations between plant polyphenols and protein amyloid aggregation establishing an increasingly solid molecular basis for the healthy effects of these molecules. In fact, several clinical trials have confirmed that most of the benefits of the Mediterranean/Asian diets can be traced back to the presence of significant amounts of these molecules, even though, in some cases, contradictory results have been reported, which highlights the need to provide further investigation on the biochemical, molecular and cell biology modifications by plant polyphenols in models of amyloid diseases.
Dr. Manuela Leri
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- amyloid aggregation
- polyphenols
- neurodegenerative diseases
- systemic diseases
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.